Draft Biocides Directive could pose threat to in vitro diagnostics (IVD)
This article was originally published in Clinica
Executive Summary
The issue of whether IVDs should be excluded from the forthcoming Biocides Directive is being discussed by DG III and DG XI of the European Commission. This is a result of pressure from EUROM II, the European Federation of Precision, Mechanical and Optical Industries, and from the UK Association of the Laboratory Supply Industry (BLWA) on the UK's Health and Safety Executive and Medical Devices Agency.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.